Business Context and Reporting Period
Company: Drugs Made In America Acquisition II Corp. (DMII)
Filing Type: Form 8-K (Current Report)
Report Date: April 22, 2026
Context: The registrant is a Cayman Islands-based special purpose acquisition company (SPAC) listed on The Nasdaq Stock Market. This filing discloses the entry into material definitive agreements regarding executive compensation and service updates for the Chief Financial Officer and Chief Executive Officer.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. As a pre-business combination SPAC, the company's financial activity in this report is limited to executive compensation obligations.
- CFO Monthly Compensation: $3,500 (unchanged from prior agreement).
- CEO Monthly Compensation: $4,500 total ($2,500 payable currently; up to $2,000 deferrable based on cash flow).
- Deferred Obligations: Deferred CEO compensation accrues as binding obligations of the Company.
Material Changes vs. Prior Period
The filing details specific updates to executive agreements compared to prior disclosures:
- CFO Equity Adjustment: The original agreement (Nov 2025) provided for 100,000 ordinary shares to Saleem Elmasri. The Updated Statement of Work (April 22, 2026) increases this entitlement to 175,000 ordinary shares due to the shares not having been previously issued. These shares are earned upon execution of a definitive agreement and issued at the closing of the initial business combination.
- CEO Compensation Formalization: Roger Bendelac was appointed CEO on February 28, 2026, without a determined compensation package. On April 22, 2026, a formal agreement was executed establishing the $4,500 monthly fee and a grant of 250,000 ordinary shares (earned upon definitive agreement execution and issued at closing).
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the Company is actively securing executive leadership for its initial business combination. Both the CFO and CEO equity grants are contingent upon the execution of a definitive agreement and the closing of the initial business combination.
Risks and Contingencies:
- Equity Dilution: The issuance of 425,000 total ordinary shares (175,000 to CFO; 250,000 to CEO) upon closing will impact the capital structure.
- Liquidity Constraints: The CEO agreement explicitly allows for deferral of up to $2,000 of monthly compensation based on the Company's cash flow, indicating potential liquidity sensitivity.
- Binding Obligations: Both current and deferred compensation amounts accrue as binding obligations of the Company.
Investor Verification Checklist
- Verify the exact number of outstanding shares prior to the issuance of the 425,000 new shares to executives upon business combination closing.
- Confirm the Company's current cash position to assess the likelihood of deferring the $2,000 monthly CEO compensation component.
- Review the full text of Exhibits 10.1 (Updated SoW) and 10.2 (CEO Compensation Agreement) for specific vesting conditions or clawback provisions not detailed in the summary.
- Monitor for the execution of a definitive business combination agreement, which triggers the equity grants.